PET/CT showed the lymphoma achieved complete response through CD19 CAR-T therapy, and gastric cancer progressed during the therapy.
      Abstract
   What is known and objective
   Anti-CD19 CAR-T cell therapy is effective in B-cell lymphoma. However, it is rarely used in lymphoma combined with other malignant tumours.
   Case description
   A relapsed/refractory follicular lymphoma (r/r FL) patient underwent anti-CD19 CAR-T cell therapy and achieved complete response to lymphoma. However, gastric adenocarcinoma (GAC) was diagnosed during the cellular therapy. After infusion of CAR-T cells, he received curative treatment for GAC, and maitained complete response in both r/r FL and GAC after the treatment.
   What is new and conclusion
   Anti-CD19 CAR-T therapy is an effective treatment for r/r FL, also provided opportunity for the sequential therapy of GAC, and remained significant quality of life afterwards.
  					  					
    			                                                                                                         
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου